Stockscreener 앱 받기
17.83
1.31%
0.23
시간 외 거래:
18.09
0.26
+1.46%
Seaport Therapeutics Inc 주식(SPTX)의 최신 뉴스
Seaport reports 6.8-fold GlyphAgo bioavailability increase - grafa.com
Seaport Therapeutics (NASDAQ:SPTX) Shares Up 3.6%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap UpWhat's Next? - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57 - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 6.3%Here's What Happened - MarketBeat
Seaport Therapeutics, Inc. $SPTX Shares Newly Acquired by State Street Corp - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap UpHere's Why - MarketBeat
Raymond James initiates Seaport Therapeutics stock coverage with strong buy on depression drug potential - Investing.com
Seaport Therapeutics, Inc. (SPTX) stock price, news, quote and history - uk.finance.yahoo.com
The Manufacturers Life Insurance Company Acquires New Stake in Seaport Therapeutics, Inc. $SPTX - marketbeat.com
Analysts Conflicted on These NA Names: SailPoint, Inc. (SAIL) and Seaport Therapeutics, Inc. (SPTX) - theglobeandmail.com
Analysts Conflicted on These NA Names: SailPoint, Inc. (SAIL) and Seaport Therapeutics, Inc. (SPTX) - theglobeandmail.com
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 4.6%Should You Buy? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX) - MarketBeat
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - biospace.com
Seaport Therapeutics at citigroup’s biopharma back to school summit 2026: platform push - Investing.com Canada
Seaport Therapeutics reports positive phase 1 trial results - investing.com
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Seaport Therapeutics reports positive phase 1 trial results By Investing.com - Investing.com Canada
PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo - TradingView
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Yahoo Finance
Seaport Therapeutics reports positive phase 1 trial results By Investing.com - Investing.com UK
RCSPureTech Health PLCPRTC's SPTX: New Positive Phase 1 GlyphAllo Data - TradingView
Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial - marketscreener.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Yahoo Finance
A 375 mg dose did not impair next-morning driving in a Seaport trial - Stock Titan
Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts - marketbeat.com
Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.ca
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - BioSpace
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - Yahoo Finance UK
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - Yahoo Finance
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 5.2%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighHere's Why - MarketBeat
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target - TipRanks
Trv Gp Vi LLC Acquires New Shares in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Stifel Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.com.au
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation - Seeking Alpha
4.70%
자본화:
|
볼륨(24시간):